Abstract: The present disclosure describes compounds of Formula (I) and Formula (II) and stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof, wherein all of the variables are as defined herein. This disclosure also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition by using the compounds and pharmaceutical compositions.

Abstract: Provided herein are compounds of Formula (I) and Formula (II) and stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof. Also provided are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition by using the compounds and pharmaceutical compositions.

Abstract: Provided herein are compounds of Formula (I) and Formula (II) and stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof. Also provided are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition by using the compounds and pharmaceutical compositions.

Abstract: Provided herein are compounds that modulate RMB39 and methods of using the compounds in RMB39-associated disorders, such as cancer (e.g., renal cell carcinoma).

Abstract: Provided herein are compounds of Formula (I) and Formula (II) and stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof. Also provided are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition by using the compounds and pharmaceutical compositions.

Abstract: The present disclosure describes compounds of Formula (I) and Formula (II) and stereoisomers, tautomers, and pharmaceutically acceptable salts or solvates thereof, wherein all of the variables are as defined herein. This disclosure also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition by using the compounds and pharmaceutical compositions.

Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: Disclosed herein is a high compression pipe clamp which in one embodiment has an inner housing and an outer housing. The hollow rigid inner housing may have a first end, an outer diameter, and a first strap bracket. The hollow rigid outer housing may have a first end, and inner diameter and a second strap bracket wherein the inner diameter of the outer housing is larger than the outer diameter of the inner housing to fit thereover. A tensioning device such as for example threaded rod is also disclosed, the threaded rod passing through the inner housing and outer housing and a threaded nut engaging the threads on the threaded rod.

Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.

Abstract: Disclosed herein is a high compression pipe clamp which in one embodiment has an inner housing and an outer housing. The hollow rigid inner housing may have a first end, an outer diameter, and a first strap bracket. The hollow rigid outer housing may have a first end, and inner diameter and a second strap bracket wherein the inner diameter of the outer housing is larger than the outer diameter of the inner housing to fit thereover. A tensioning device such as for example threaded rod is also disclosed, the threaded rod passing through the inner housing and outer housing and a threaded nut engaging the threads on the threaded rod.

Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: Disclosed herein is a high compression pipe clamp which in one embodiment has a hollow rigid inner housing and a hollow rigid outer housing. The hollow rigid inner housing may have a first end, an outer diameter, and a first strap bracket. The hollow rigid outer housing may have a first end, and inner diameter and a second strap bracket wherein the inner diameter of the outer housing is larger than the outer diameter of the inner housing to fit thereover. A threaded rod is also disclosed, the threaded rod passing through the inner housing and outer housing and a threaded nut engaging the threads on the threaded rod.

Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: The present invention relates to spirocarbamate compounds of Formula (I) in which R1, (R2)Y, R3, R4, X and A have the meanings given in the specification. The invention further provides pharmaceutical compositions containing the compounds or pharmaceutically acceptable salts thereof and relates to their use of these compounds as TRPV4 antagonists in treating or preventing conditions associated with TRPV4 imbalance.

Abstract: The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists.

Abstract: Disclosed herein is a high compression pipe clamp which in one embodiment has a hollow rigid inner housing and a hollow rigid outer housing. The hollow rigid inner housing may have a first end, an outer diameter, and a first strap bracket. The hollow rigid outer housing may have a first end, and inner diameter and a second strap bracket wherein the inner diameter of the outer housing is larger than the outer diameter of the inner housing to fit thereover. A threaded rod is also disclosed, the threaded rod passing through the inner housing and outer housing and a threaded nut engaging the threads on the threaded rod.

Abstract: A deactivator having a deactivation antenna coil and a capacitor to store energy. The deactivator converts the stored energy to an alternating current over a deactivation period to generate a deactivation magnetic field when driven through the deactivation antenna coil during the deactivation period. The alternating current defines a ring down envelope during the deactivation period. An energy recovery module having an electrical impedance is coupled to the deactivator to recover a portion of the energy converted to the alternating current during a portion of the deactivation period based on the impedance. Other embodiments are described and claimed.